Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

Metabolism ◽  
2000 ◽  
Vol 49 (6) ◽  
pp. 709-717 ◽  
Author(s):  
Fernando Rodriquez de Fonseca ◽  
Miguel Navarro ◽  
Elvira Alvarez ◽  
Isabel Roncero ◽  
Julie A. Chowen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Body Weight Loss ◽  
Central Effects ◽  
Receptor Agonists ◽  
Obese Rats ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

A novel GIP analogue, ZP 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents

2017 ◽  
Vol 20 (1) ◽  
pp. 60-68 ◽  
Author(s):  
Pia K. Nørregaard ◽  
Maria A. Deryabina ◽  
Pernille Tofteng Shelton ◽  
Jacob U. Fog ◽  
Jens R. Daugaard ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Glycaemic Control ◽  
Body Weight Loss ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

The effects of ileal transposition on food intake and body weight loss in VMH-obese rats

1982 ◽  
Vol 35 (2) ◽  
pp. 284-293 ◽  
Author(s):  
H S Koopmans ◽  
A Sclafani ◽  
C Fichtner ◽  
P F Aravich
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Food Intake ◽  
Body Weight Loss ◽  
Ileal Transposition ◽  
Obese Rats

scholarly journals Effect of grapefruit juice and sibutramine on body weight loss in obese rats

2015 ◽  
Vol 9 (8) ◽  
pp. 265-273 ◽  
Author(s):  
Farouk Hadir ◽  
S Mahmoud Sawsan ◽  
A El Sayeh Bahia ◽  
A Sharaf Ola
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Grapefruit Juice ◽  
Body Weight Loss ◽  
Obese Rats

scholarly journals How glucagon-like peptide 1 receptor agonists work

2021 ◽  
Author(s):  
Christine Rode Andreasen ◽  
Andreas Andersen ◽  
Filip Krag Knop ◽  
Tina Vilsbøll
Keyword(s):  
Body Weight ◽  
Therapeutic Potential ◽  
Clinical Effects ◽  
Glucose Lowering ◽  
Receptor Agonists ◽  
Reduce Body Weight ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Clinical Utilisation

Recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of actions, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.

scholarly journals Effect of Chronic Central Administration of Glucagon-Like Peptide-1 (7-36) Amide on Food Consumption and Body Weight in Normal and Obese Rats

1998 ◽  
Vol 6 (2) ◽  
pp. 147-156 ◽  
Author(s):  
Harry R. Davis ◽  
Deborra E. Mullins ◽  
Jesse M. Pines ◽  
Lizbeth M. Hoos ◽  
Constance F. France ◽  
...  
Keyword(s):  
Body Weight ◽  
Food Consumption ◽  
Central Administration ◽  
Obese Rats ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Matteo Monami ◽  
Ilaria Dicembrini ◽  
Niccolò Marchionni ◽  
Carlo M. Rotella ◽  
Edoardo Mannucci
Keyword(s):  
Body Weight ◽  
Weight Reduction ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Pharmacological Interventions ◽  
Receptor Agonists ◽  
Cochrane Database ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs), approved as glucose-lowering drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight. An extensive Medline, Cochrane database, and Embase search for “exenatide,” “liraglutide,” “albiglutide,” “semaglutide,” and “lixisenatide” was performed, collecting all randomized clinical trials on humans up to December 15, 2011, with a duration of at least 24 weeks, comparing GLP-1 receptor agonists with either placebo or active drugs. Twenty two (7,859 patients) and 7 (2,416 patients) trials with available results on body weight at 6 and 12 months, respectively, were included. When compared with placebo, GLP-1RAs determine a reduction of BMI at 6 months of −1.0 [−1.3; −0.6] kg/m2. Considering the average BMI at baseline (32.4 kg/m2) these data means a weight reduction of about 3% at 6 months. This result could seem modest from a clinical standpoint; however, it could be affected by many factors contributing to an underestimation of the effect of GLP-1RA on body weight, such as non adequate doses, inclusion criteria, efficacy of GLP-1RA on reducing glycosuria, and association to non-pharmacological interventions not specifically aimed to weight reduction.

Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1291-P
Author(s):  
CRAIG I. COLEMAN ◽  
WILLIAM H. HERMAN ◽  
SHIVANI PANDYA ◽  
LI WANG ◽  
ONUR BASER ◽  
...  
Keyword(s):  
Body Weight ◽  
Real World ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document